Although the addition of recombinant IL-6 and IL-8 did not stimulate LDL degradation in the in AML cells, we tested the direct addition of an IL-6 neutralizing antibody to AML cells from 2 patients with basal LDL degradation rates of 3.2 and 1.7 ng/h/106 cells. The gene discussed is CXCL8; the disease is acute myeloid leukemia.